ASCO 2009: Significant Developments in Context
The recent ASCO meeting was attended by around 30,000 cancer researchers and physicians and over 4,000 abstracts covering a wide range of clinical trial results and related topics were presented. How do you make sense of it all and, more importantly, what were the developments that were really important?
This new FirstWord Dossier brings clarity and insight
FirstWord’s new analysis of the latest ASCO meeting highlights and presents selected information on the significant announcements from the conference in an easy-to-use digest. FirstWord’s team of experienced medical journalists were on-hand to critically review and report the latest developments and thinking and this information, augmented by pre- and post-conference data released by developers, is the basis of this detailed 175-page research dossier.
Just a taste of the content ...
Eli Lilly’s announcement regarding latest research findings on Alimta (pemetrexed) in the treatment of advanced - other than predominantly squamous - non-small-cell lung cancer (NSCLC), was regarded by many as one of the highlights of the conference.
Significant announcements also came from:
This research provides:
This new FirstWord Dossier brings clarity and insight
FirstWord’s new analysis of the latest ASCO meeting highlights and presents selected information on the significant announcements from the conference in an easy-to-use digest. FirstWord’s team of experienced medical journalists were on-hand to critically review and report the latest developments and thinking and this information, augmented by pre- and post-conference data released by developers, is the basis of this detailed 175-page research dossier.
Just a taste of the content ...
Eli Lilly’s announcement regarding latest research findings on Alimta (pemetrexed) in the treatment of advanced - other than predominantly squamous - non-small-cell lung cancer (NSCLC), was regarded by many as one of the highlights of the conference.
Significant announcements also came from:
- Pfizer (PF-02341066) – NSCLC
- Seattle Genetics (SGN-35) - Hodgkin lymphoma/anaplastic large cell lymphoma
- Roche (trastuzumab) – gastric cancer
- Genentech/Roche/Immunomedics (trastuzumab-DM1) – breast cancer
- AstraZeneca (gefitinib) – NSCLC
- Cancer Research UK (gemcitabine/cisplatin combination) - biliary-tract cancer
- Roche (erlotinib; erlotinib/bevacizumab) – NSCLC
- Biovest International (BiovaxID) – follicular lymphoma
This research provides:
- An easy and well-indexed reference to the latest developments by cancer type or treatment area.
- Current thinking with the report focusing on developments at the conference, updated with the latest product information.
- An objective and independent review free from commercial spin.
- A cost-effective and time-saving appraisal giving you the insight you need with the minimum of effort.
Executive Summary
Chemotherapy-Induced Conditions
Brain Cancer
Head/Neck Cancer
Neuroblastoma
Breast Cancer
Cervical Cancer
Ovarian Cancer
Liver Cancer
Biliary-Tract Cancer
Stomach Cancer
Gastrointestinal Cancer
Oesophageal Cancer
Colorectal Cancer
Kidney Cancer
Lung Cancer
Malignant Mesothelioma
Melanoma
Uveal Melanoma
Pancreatic Cancer
Prostate Cancer
Multiple Cancers
Solid Tumours
Leukaemia
Lymphoma
Multiple Myeloma
Chemotherapy-Induced Conditions
Brain Cancer
Head/Neck Cancer
Neuroblastoma
Breast Cancer
Cervical Cancer
Ovarian Cancer
Liver Cancer
Biliary-Tract Cancer
Stomach Cancer
Gastrointestinal Cancer
Oesophageal Cancer
Colorectal Cancer
Kidney Cancer
Lung Cancer
Malignant Mesothelioma
Melanoma
Uveal Melanoma
Pancreatic Cancer
Prostate Cancer
Multiple Cancers
Solid Tumours
Leukaemia
Lymphoma
Multiple Myeloma
